How do B vitamins affect homocysteine and brain/CV health?

How it works

Riboflavin (B2) and choline or betaine also participate in homocysteine clearance via the betaine-homocysteine methyltransferase pathway (alternative to the folate-dependent remethylation route). Deficiency in B12, folate, or B6 raises plasma homocysteine; folate deficiency dominates in folate-unfortified populations, B12 deficiency in older adults due to age-related malabsorption. MTHFR C677T polymorphism: TT homozygotes have around 20% residual MTHFR enzyme function vs 66% in CC wild-type and 56% in CT; TT carriers run modestly higher homocysteine, particularly when folate intake is low.

Effective dose

Lower-dose preventive supplements (folic acid 400 mcg + B12 6-25 mcg + B6 1.4 mg) reduce homocysteine in adequacy-deficient populations but with smaller effect. Standard folic acid supplementation effectively normalises homocysteine in MTHFR TT carriers; the marketing claim that TT carriers require methylfolate is not supported by trial evidence (methylfolate is more bioavailable and is the form circulating in plasma, but it is not necessary in the way often implied). Pre-existing B12 deficiency must be addressed before isolated folic acid because folate alone can mask megaloblastic anaemia and allow neurological B12 deficiency to progress.

Forms compared

Plasma homocysteine: routine non-fasting blood test in many UK labs. Conventional thresholds: below 10 micromol/L normal; 10-15 mildly elevated; 15-30 moderately elevated; 30-100 intermediate hyperhomocysteinaemia; above 100 severe (typically homocystinuria from CBS or severe MTHFR deficiency). Diurnal and methionine-load variation is small; spot non-fasting samples are acceptable.

Timing

CSPPT primary-stroke-prophylaxis trial showed first-stroke reduction over 4.5 years follow-up. HOPE-2, VITATOPS, VISP, and NORVIT reductions in homocysteine were measured at 1-3 years follow-up; primary composite outcomes were measured at 3-5 years. Cognitive and brain-structural changes (VITACOG) were measured at 24 months. Bone fracture endpoints in B-PROOF and similar trials were measured over 2-3 years.

Safety profile

Hyperhomocysteinaemia above 100 micromol/L warrants specialist assessment for inborn errors (homocystinuria, severe MTHFR deficiency). Elevated homocysteine in older adults should prompt investigation for B12 malabsorption (intrinsic factor antibodies, parietal cell antibodies, coeliac serology) before empirical repletion.

Special populations

Folate-unfortified populations (UK, Europe): folate deficiency dominates as a homocysteine driver. Folate-fortified populations (US, Canada, Chile): B12 deficiency dominates. Vegans and vegetarians: B12 deficiency more common. Long-term metformin, PPI, or H2 receptor antagonist users: monitor for B12 deficiency over years. Anticonvulsant users: may affect B12 status.

Interactions

Methotrexate: a folate antagonist; B-vitamin supplementation in users on methotrexate requires specialist input. Phenytoin and other anticonvulsants: may lower folate and B12 status. Metformin: long-term use lowers B12. PPIs and H2 receptor antagonists: chronic use lowers B12. Levodopa: B6 accelerates peripheral decarboxylation when carbidopa is not co-prescribed (modern combinations not affected). Nitrous oxide exposure: inactivates B12 by oxidising cobalt centre.

Guideline positions

Observational meta-analyses: Wald 2002 BMJ and Klerk 2002 JAMA reported each 5 micromol/L higher homocysteine associated with around 30% higher CHD risk and 60% higher stroke risk. Spence and Hankey 2017 IPD reanalysis of VISP and VITATOPS found that in users with normal renal function not exposed to high-dose cyanocobalamin, B vitamins reduced stroke RR 0.78 (95% CI 0.67-0.90). CSPPT primary-stroke-prophylaxis in 20,702 folate-naive Chinese hypertensives showed first-stroke reduction around 21% with enalapril + folate vs enalapril alone. VITACOG: 271 over-70s with MCI; whole-brain atrophy rate 0.76%/year active vs 1.08%/year placebo (29.6% reduction overall; around 50% reduction in those with baseline homocysteine above the median). VITACOG cognitive analysis (de Jager 2012 PMID 21780182): slower cognitive decline particularly in high-baseline-homocysteine subgroup. Bone evidence: van Meurs 2004 NEJM and McLean 2004 NEJM established epidemiological association between elevated homocysteine and fracture risk; B-vitamin RCTs for fracture prophylaxis (e.g. B-PROOF) have been mostly null.

Practical framework

Honest reading of the evidence: cardiovascular benefit is real for stroke specifically in selected populations (Spence and Hankey 2017 IPD, CSPPT), not for myocardial events broadly (HOPE-2, VITATOPS, VISP, NORVIT primary composites null). Cognitive benefit: B-vitamin therapy can slow cognitive decline in MCI users with raised homocysteine at VITACOG doses; effect not generalisable to routine supplementation in healthy older adults with normal homocysteine. Bone: epidemiological signal robust, intervention benefit not established. Standard folic acid supplementation effectively normalises homocysteine in MTHFR TT carriers; methylfolate is not necessary. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

Common misconceptions

Claim: B-vitamin supplementation in healthy older adults with normal homocysteine slows cognitive decline. VITACOG was conducted in MCI users with raised homocysteine; Cochrane reviews of folic acid alone or B12 alone in healthy older adults are mostly null.

Claim: starting folate when both B12 and folate are low is fine. The folate trap (haematological response masks while neurological damage progresses); always check B12 alongside folate; address B12 first or in parallel.

Claim: homocysteine above 15 micromol/L always indicates a B-vitamin deficiency. Renal impairment, hypothyroidism, and certain medications also raise homocysteine; investigation should rule out other causes.